This summary was created by AI, based on 15 opinions in the last 12 months.
Thermo Fisher Scientific (TMO-N) is a leader in the healthcare services technology space, with a strong focus on biopharma and life sciences. Despite recent stock price fluctuations, experts agree that the company's long-term fundamentals remain solid, particularly as it enters a red-hot period in the industry. The company has a strong track record of consolidating the healthcare space and is well-positioned for growth, with a focus on R&D and acquisitions. Overall, experts believe that the current pullback in stock price presents a buying opportunity for the long term.
It's retraced a big move, so it's buying opportunity. Healthcare services technology is great place to be.
Last week, they reported strong earnings and an in-line full-year forecast, but stocks fell nearly 5%. That was a sell-the-news reaction, he thinks. Management said that 2023 was their transition year when they unwound excess inventory and 2024 is their recovery year, particularly in the second half. Buy it now. Macro trends: he thinks we're starting a huge innovation cycle in pharma in weight-loss drugs among others, all helped by generative AI. Biopharma is entering a red-hot period after years of pain.
He bought this in mid-2023 on a dip. It's been consolidating the healthcare space for the last 10 years. Are #1 in this space. He expects sales and their PE to improve.
She bought in summer, stock's not done too much, so it gets to be a Top Pick again. Vast array of picks and shovels to the healthcare industry. Reduced guidance a couple of times, very unusual for them: weakness in China, general caution in spending, and Covid-double-ordered inventory destocking. Likes long-term fundamentals of healthcare industry, and TMO will participate. Yield is 0.3%.
(Analysts’ price target is $536.48)Is up 11% in the past month. Their customers have finished clearing out their excess inventory after a year. Better US-China relations means more sales for TMO.
TMO is a leader in life sciences and diagnostics. He recently added. The entire sector has some over-supply. This is the bottom of the cycle. Lower risk, less upside, more diversified. Historically, good at acquisitions. Good long-term hold, but right now it's all about waiting for funding to come back to the sector.
When the cycle turns, both will do well and will probably outperform.
It is the leading global player in life sciences and tools. It provides drug companies, pharmaceuticals and labs and in fact is vital to the pharmaceutical industry in helping with drug development. The overhang is weakness in China and bio-tech companies but this should be a temporary headwind. With a good management team it is growing in the U.S. with several acquisitions. The pull back makes it a good time to buy for the long term. Buy 21 Hold 6 Sell 1
(Analysts’ price target is $592.27)Spend the last ~20 years consolidating scientific/diagnostics tools market.
Very strong demand for health care products.
Strong pipeline of R&D.
Expecting a 5-7% revenue growth & double digit earnings growth.
Great compounding business for long term shareholder.
Leader in technology in sectors that are solid but not hot. Largest player in devices needed for research. Successfully integrates acquisitions. Pick and shovels. Revenue growth of 8-10%. Not cheap, but foresees 10-15% growth per annum for 5-6 years. Yield is 0.26%.
(Analysts’ price target is $617.21)Healthcare products and services. Benefitted from Covid, and financial windfall can be used to reinvest in the business. Growth will be flat this year and then pick up. Raised growth target to 7-9% annually on topline. 82% of revenue is recurring, a defensive characteristic. Yield is 0.26%.
(Analysts’ price target is $619.33)Leading health care providers to pharma companies.
Excellent at M&A the past 10 years.
Large R&D pipeline.
Also good in hardware sales for new drugs.
Benefited from Covid-19 pandemic.
Recent share price weakness presenting good buying opportunity.
Expecting growth of revenue and earnings.
Recently bought this. TMO benefitted during Covid because companies used their products and services. Shares are off 22% from highs. Grows organically and from M&A. They generate cash flow and earnings, which will be down this year. But they invest in companies and R&D well. Pays a small dividend though.
(Analysts’ price target is $623.56)October-November marked a major low. Range-bound between $600-520. As long as it doesn't take out the $520 level to the downside, doesn't mind nibbling here for the longer term. He expects we're starting a new 4-year cycle for a 3-5 year bull market. See his Top Picks.
It has differing moving parts and has a growth component - lab samples go to their products associated with lab work. Personalized medicine is a major growth area and means more specific types of testing. This will benefit TMO
Thermo Fisher Scientific is a American stock, trading under the symbol TMO-N on the New York Stock Exchange (TMO). It is usually referred to as NYSE:TMO or TMO-N
In the last year, 8 stock analysts published opinions about TMO-N. 8 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Thermo Fisher Scientific.
Thermo Fisher Scientific was recommended as a Top Pick by on . Read the latest stock experts ratings for Thermo Fisher Scientific.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
8 stock analysts on Stockchase covered Thermo Fisher Scientific In the last year. It is a trending stock that is worth watching.
On 2024-04-25, Thermo Fisher Scientific (TMO-N) stock closed at a price of $571.73.
Not a major growth company, but will grow steady. ~7% top line growth expected to continue. ~10% share price appreciation expected going forward. Will continue to hold in portfolio.